Open AccessProvision of Gefitinib as Targeted Therapy in Lung Adenocarcinoma with EGFR Mutation and Brain Metastatic
Author(s) -
Komang Sri Rahayu Widiasari
Publication year - 2019
Publication title -
malang respiratory journal
Language(s) - English
Resource type - Journals
eISSN - 2745-7842
pISSN - 2722-6492
DOI - 10.21776/ub.mrj.2019.001.01.3
Subject(s) - gefitinib , epidermal growth factor receptor , adenocarcinoma , medicine , histopathology , oncology , lung , targeted therapy , lung cancer , metastasis , cancer research , pathology , cancer
Adenocarcinoma is a malignant epithelial tumor with glandular differentiation or mucin production. Adenocarcinoma covers 30% of lung cancers in Europe and America. This report described a case of an unusual chronic headache since 3 years ago without any complementing symptom except for nausea. The primary tumor was detected with Thorax CT scan and confirmed by histopathology examination. Patient treated with gefitinib (1 x 250 mg) and showed a satisfying result. Gefitinib, as first-line therapy for patients with epidermal growth factor receptor ( EGFR) mutation, was effective and well-tolerated in this patient.